RNAC
Cartesian TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
RNAC vs peer average
95/100
RNAC vs. peer average (A vs. D)
Grade spread
B 1 · C 2 · D 3 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
CABA is the first available peer comparator.
Thematic autoimmune cell-therapy comparator, but not a direct operating or valuation peer because its lead approach is CD19-directed while RNAC is developing an autologous BCMA mRNA CAR-T program.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
RNAC
Cartesian Therapeutics
CABA
Cabaletta Bio
Grade
A
D
Momentum
89
9
Value
41
41
Sentiment
61
73
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs CABA
RNAC / CABA
Grade Position
Above peers
RNAC vs. peer average (A vs. D)
95/100
Momentum
89
RNACValue
41
RNACSentiment
61
CABARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs RNAC
CABA is the first peer returned for this comparison set.